Pulmatrix (NASDAQ:PULM) Shares Pass Above 50 Day Moving Average – What’s Next?

Pulmatrix, Inc. (NASDAQ:PULM)’s share price passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $2.48 and traded as high as $2.49. Pulmatrix shares last traded at $2.49, with a volume of 83,004 shares changing hands.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Pulmatrix in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Pulmatrix Price Performance

The stock has a 50-day simple moving average of $2.48 and a 200 day simple moving average of $3.65.

Pulmatrix (NASDAQ:PULM) last released its earnings results on Thursday, February 26th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter.

Institutional Trading of Pulmatrix

An institutional investor recently bought a new position in Pulmatrix stock. Dimensional Fund Advisors LP acquired a new position in shares of Pulmatrix, Inc. (NASDAQ:PULM) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 10,780 shares of the biotechnology company’s stock, valued at approximately $52,000. Dimensional Fund Advisors LP owned about 0.30% of Pulmatrix at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.84% of the company’s stock.

Pulmatrix Company Profile

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).